Shire/Actelion rumors highlight M&A buzz in orphan space
This article was originally published in Scrip
Executive Summary
Reports of a £12.4bn ($18.9bn) preliminary approach sent Shire's share price down by 2.75% to £53.05 on the London Stock Exchange on 8 June, while Actelion's stock rose nearly 10% to an all-time high of CHF144.50 on the Swiss exchange, pushing its market capitalization up to CHF16.5bn ($17.5bn).
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: